Loading...
Loading...
LUND, Sweden, Nov. 4, 2013 (GLOBE NEWSWIRE) --
Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today that its partner Teva Pharmaceutical Industries Ltd. TEVA will initiate a further clinical trial, LIBRETTO, to evaluate the
efficacy, safety and tolerability of two doses of oral laquinimod (0.6 and 1.2
mg/day), compared to interferon beta-1a, in patients with relapsing remitting
multiple sclerosis. Primary endpoint of the study will be brain atrophy. For
further details please see www.clinicaltrials.gov where the trial will appear
during this week.
About laquinimod
Laquinimod is an oral, investigational, CNS-active immunomodulator with a novel
mechanism of action being developed for the treatment of relapsing-remitting MS
(RRMS). The global Phase III clinical development program evaluating oral
laquinimod in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase
III laquinimod trial, CONCERTO, is evaluating two doses of the investigational
product (0.6mg and 1.2mg) in approximately 1,800 patients for up to 24 months.
The primary outcome measure will be time to confirmed disability progression as
measured by the EDSS.
In addition to the MS clinical studies, laquinimod has concluded Phase II of
development for Crohn's disease and lupus nephritis. Further studies are
planned to determine the effectiveness of laquinimod in treating patients with
Huntington's disease and Alzheimer's disease.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod has concluded Phase II development for Crohn's and
Lupus. The company also has one additional project in clinical development, the
orally administered compound paquinimod (57-57) for systemic sclerosis. Please
visit www.activebiotech.com for more information.
For further information:
Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson@activebiotech.com
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.
Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 08:30 am CET on November 4, 2013.
Active Biotech's partner Teva initiates a further clinical trial : http://hugin.info/1002/R/1740139/584195.pdf
[HUG#1740139]
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Press Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in